Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiogenFRA:IDP -0.80%78 3-1 Month Momentum % is 13.01% as of Aug. 09, 2026. GuruFocus rates FRA:IDP with a GF Score™ of 78/100 and a GF Value™ of €168.69 (Fairly Valued). The stock has 10 warning signs investors should review. Among 1,019 Drug Manufacturers companies, Biogen ranks better than 79.59% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-09), Biogen's 3-1 Month Momentum % is 13.01%.
The industry rank for Biogen's 3-1 Month Momentum % or its related term are showing as below:
FRA:IDP's 3-1 Month Momentum % is ranked better than 79.59% of 1019
companies
in the Drug Manufacturers industry
Industry Median: -7.87
vs FRA:IDP: 13.01
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Biogen 3-1 Month Momentum % Related Terms
FRA:IDP vs OGN, AMRN, SCLX: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - General subindustry, Biogen's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogen's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Biogen's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogen (FRA:IDP) has a 3-1 Month Momentum % of 13.01% as of Aug. 09, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Biogen and its competitors. According to the industry distribution chart, Biogen ranks #208 out of 1019 companies in the Drug Manufacturers industry, placing it in the top 20.4%.
Is Biogen's 3-1 Month Momentum % too high?
Biogen's current 3-1 Month Momentum % is 13.01%. Based on the distribution chart, Biogen ranks #208 out of 1019 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Biogen has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biogen's 3-1 Month Momentum % compare to OGN and AMRN?
According to the Drug Manufacturers industry distribution chart, Biogen ranks #208 out of 1019 companies for 3-1 Month Momentum %. This places Biogen in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Biogen and its competitors. Biogen's current 3-1 Month Momentum % is 13.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (FRA:IDP) is currently considered Fairly Valued. The stock's GF Value™ is €168.69, compared to a current price of €176.62 — trading 4.7% above its estimated fair value. The current 3-1 Month Momentum % is 13.01%. Biogen's overall GF Score™ is 78/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Biogen (FRA:IDP), the current 3-1 Month Momentum % is 13.01% as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogen (FRA:IDP) Overvalued in 2026?
Based on GuruFocus' analysis, Biogen stock appears to be overvalued.
The current stock price of €176.62 is trading 4.7% above its estimated GF Value™ of €168.69.
GuruFocus considers Biogen to be Fairly Valued.
Key valuation signals for FRA:IDP:
3-1 Month Momentum %: 13.01%
GF Value™: €168.69 vs. price of €176.62 (4.7% above fair value)
No single metric tells the full story. See the FRA:IDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
78GF Score
Get the complete analysis for FRA:IDP
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IDP has been successfully added to your 
